Foundation Medicine is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.
FoundationOne® CDx is a next-generation sequencing-based diagnostic test, which should be used to inform the use of immunotherapies, identify alternative options or identify trial opportunities.1–6
What is FoundationOne® CDx?
Genes and biomarkers
Comprehensive assessment in a single test
FoundationOne® CDx provides a detailed analysis of the tumour genome, analysing 324 known cancer-relevant genes across the four main classes of genomic alterations, in addition to TMB and MSI, to inform treatment decision-making.1,7,12,13*
FoundationOne® CDx should be used proactively, at the first point of clinical uncertainty in any metastatic solid tumour
FoundationOne® CDx is a single tissue test suitable for most patients with malignant solid tumour cancers.7 It is most frequently used in patients with advanced, recurrent or metastatic cancers who have exhausted standard of care treatment options. A validated testing process, led by scientists and academics, produces a genomic report, typically within 14 days of receiving a suitable tumour sample. The FoundationOne® test (a prior version of FoundationOne® CDx) has been analytically validated with high sensitivity scores of 95–99% across the range of genomic alterations and a high specificity (positive predictive value >99%).1
FoundationOne® CDx gene list
FoundationOne CDx gene list
The Roche Foundation Medicine platform has been analytically validated
FoundationOne® CDx is based on our analytically and clinically validated comprehensive platform.1 A practical validation strategy to determine accuracy, including sensitivity and specificity, was applied to the prior FoundationOne® platform. Results demonstrated that the platform had a test sensitivity of 95–99% across alteration types and a high specificity with a positive predictive value of more than 99%. Application of the test to 2,221 clinical cases revealed clinically actionable alterations in 76% of tumours, three times the number of actionable alterations detected by existing diagnostic tests.1
What is the difference between analytical and clinical validation?
The FoundationOne® CDx report provides a clear and concise view of the important information needed to support your clinical decision-making‡
The report gives detailed information on clinically relevant alterations across 324 cancer-relevant genes to inform the use of immunotherapies, identify alternative therapy options or identify trial opportunities.7
The FoundationOne® CDx platform provides clear, detailed information to support confident clinical decision-making
FoundationOne® CDx may detect clinically relevant genomic alterations that common diagnostic techniques such as polymerase chain reaction (PCR) / immunohistochemistry (IHC) / fluorescence in situ hybridisation (FISH), and multigene hotspot next-generation sequencing tests may miss, which could help direct clinicians to treatment options not previously considered.§2,3,5,15,16
FoundationOne® CDx is a single tissue test
The FoundationOne® CDx report delivers a complete set of results from a single test sample, thereby saving tissue.7
Order FoundationOne® CDx
Ordering a FoundationOne® CDx test is simple and convenient
For more information about the ordering process, contact the Roche Foundation Medicine Customer Care Team: